Abstract
The clinical and financial cost of statin-associated muscle symptoms (SAMS) for patients, providers, and the overall health system can be highly impactful. The high prevalence of SAMS warrants an assessment of the clinical and financial burden to patients, providers, and the health system. Clinical and financial costs include the need for additional laboratory testing, clinic visits, additional prescriptions or modifications of prescriptions, and potential to have cardiovascular (CV) events related to stopping or reducing the dose of statin therapy. Providers’ clinical and financial costs include increased utilization to educate, screen for, and modify therapy in order to treat and prevent SAMS in patients subsequently decreasing the ability to see or treat additional patients. The health system clinical and financial costs relate to decreased ability to see additional patients or increase access to patients if managing or assessing additional patients with SAMS, added resources for additional laboratory testing, and increased resources associated with treating new CV events in patients who have stopped or decreased statins secondary to SAMS and have subsequent CV events. A focus on preventing and managing SAMS requires a focused effort to ensure the increased clinical and financial costs do not overburden the patient, providers, and the health system as a whole.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wai MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7:472–84.
Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8:S58–71.
Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statin-associated myalgia – a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015;178:111–6.
Robinson CD, Blair TL, Horne BD, et al. Hypothyroidism as a risk factor for statin intolerance. J Clin Lipidol. 2014;8:401–7.
Zaleski AL, Taylor BA, Thompson PD. Coenzyme Q10 as treatment for statin-associated muscle symptoms – a good idea, but. Adv Nutr. 2018;9:519S–23S.
Graham JH, Sanchez RJ, Saseen JJ, et al. Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. J Clin Lipidol. 2017;11(1):70–9.
Colantonio LD, Deng L, Chen L, et al. Medical expenditures among medicare beneficiaries with statin-associated adverse effects following myocardial infarction. Cardiovasc Drugs Ther. 2018;32(6):601–10.
Colantonio LD, Kent ST, Huang L, Chen L, Monda KL, Serban MC, et al. Algorithms to identify statin intolerance in Medicare administrative claim data. Cardiovasc Drugs Ther. 2016;30:525–33.
Choudhry NK, ShrankWH LRL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15:457–64.
Centers for Medicare & Medicaid Services. Draft initial release of the 2019 Part C & D star ratings technical notes. Last updated September 4, 2018. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/Downloads/2019-Technical-Notes-preview-2.pdf. Accessed 15 May 2019.
CMS lab fee schedule. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files-Items/19CLABQ1.html. Accessed 30 July 2019.
CMS physician fee schedule. https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx. Accessed 30 July 2019.
https://www.goodrx.com/. Accessed 30 July 2019.
Ryder S, Fox K, Rane P, et al. A systematic review of direct cardiovascular event costs: an international perspective. PharmacoEconomics. 2019;37(7):895–919.
Conflicts of Interest
The authors have none to disclose. No funding was received in the publication of this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Marrs, J.C., Kostoff, M.D. (2020). The Clinical and Financial Cost of SAMS. In: Thompson, P., Taylor, B. (eds) Statin-Associated Muscle Symptoms. Contemporary Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-33304-1_17
Download citation
DOI: https://doi.org/10.1007/978-3-030-33304-1_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-33303-4
Online ISBN: 978-3-030-33304-1
eBook Packages: MedicineMedicine (R0)